Publication

2019
・Moriyama M, Koshiba T, Ichinohe T. Influenza A virus M2 protein triggers mitochondrial DNA-mediated 　 　antiviral immune responses. Nat Commun. 2019 Oct 11;10(1):4624. [Link]

・Moriyama M, Ichinohe T. High ambient temperature dampens adaptive immune responses to influenza A 　virus infection. Proc Natl Acad Sci U S A. (in press) [Link]

・Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe Acute Respiratory Syndrome Coronavirus Viroporin 　3a Activates the NLRP3 Inflammasome. Front Microbiol. (in press) [Link]

2018
・Furusho K, Shibata T, Sato R, Fukui R, Motoi Y, Zhang Y, Saitoh SI, Ichinohe T, Moriyama M, Nakamura S, 　Miyake K. Cytidine deaminase enables Toll-like receptor 8 activation by cytidine or its analogs. Int 　
　Immunol. (in press)

・Moriyama M, Igarashi M, Koshiba T, Irie T, Takada A, Ichinohe T. Two conserved amino acids
　within the NSs of SFTS phlebovirus are essential for anti-interferon activity. J Virol. 2018 Sep 12;92(19). 　pii: e00706-18. [Link]

・Maruzuru Y, Ichinohe T, Sato R, Miyake K, Okano T, Suzuki T, Koshiba T, Koyanagi N, Tsuda S, Watanabe
　M, Arii J, Kato A, Kawaguchi Y. Herpes Simplex VIrus 1 VP22 Inhibits AIM2-dependent Inflammasome
　Activation to Enable Efficient Viral Replication.Cell Host & Microbe. Feb 14;23(2):254-265.

・Walenna NF, Kurihara Y, Chou B, Ishii K, Soejima T, Itoh R, Shimizu A, Ichinohe T, Hiromatsu K.
　Chlamydia pneumoniae exploits adipocyte lipid chaperone FABP4 to facilitate fat mobilization and
　 intracellular growth in murine adipocytes. Biochem Biophys Res Commun. Jan 1;495(1):353-359.

2017
・Saitoh SI, Abe F, Kanno A, Tanimura N, Mori Saitoh Y, Fukui R, Shibata T, Sato K, Ichinohe T,
　 Hayashi M, Kubota K, Kozuka-Hata H, Oyama M, Kikko Y, Katada T, Kontani K, Miyake K.
　TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells.
　Nat Commun. 2017 Nov 17;8(1):1592.

・Moriyama M, Takeyama H, Hasegawa H, Ichinohe T*. Induction of lung CD8+ T cell responses by
　consecutive inoculations of a poly(I:C) infleunza vaccine. Vaccine. 2017 Dec 4;35(48 Pt B):6620-6626.

・Koyanagi N, Imai T, Shindo K, Sato A, Fujii W, Ichinohe T, Takemura N, Kakuta S, Uematsu S, Kiyono H,
　Maruzuru Y, Arii J, Kata A, Kawaguchi Y. Herpes simplex virus-1 evasion of CD8+ T cell accumulation
　contributes to viral encephalitis. J Clin Invest. 2017 Oct 2;127(10):3784-3795.

・Moriyama M, Chino S, Ichinohe T*. Consecutive inoculations of influenza virus vaccine and poly(I:C)
　protects mice against homologous and heterologous virus challenge.
　Vaccine. 2017 Feb 15;35(7):1001-1007.

2016
・Moriyama M, Chen IY, Kawaguchi A, Koshiba T, Nagata K, Takeyama H, Hasegawa, H, Ichinohe T*.
　The RNA- and TRIM25-binding domains of infleunza virus NS1 protein are essential for suppression of
　NLRP3 inflammasome-mediated IL-1β secretion. J Virol. 2016 Mar 28;90(8):4105-14. [Link]

2015
・Chen IY, Ichinohe T*. Response of host inflammasomes to viral infection.
　Trends Microbiol. 2015 Jan;23(1):55-63.

2014
・Yoshizumi T, Ichinohe T, Sasaki O Otera H, Kawabata SI, Mihara K, Koshiba T. Influenza A
　virus protein PB1-F2 translocates into mitochondria via Tom40 channels and impairs innate
　immunity. Nat Commun. 2014 Aug 20;5:4713. doi: 10.1038/ncomms5713

・Yamazaki T, Ichinohe T*. Inflammasomes in antiviral immunity: clues for influenza vaccine
　development. Clin Exp Vaccines Res. 2014 Jan;3(1):5-11.

2013
・Ichinohe T*, Yamazaki T, Koshiba T, Yanagi Y. Mitochondrial protein mitofusin 2 is required for
　NLRP3 inflammsome activation after RNA virus infection. Proc Natl Acad Sci U S A. 2013 Oct
　29;110(44):17963-8.

・Pang IK, Ichinohe T, Iwasaki A. IL-1R signaling in dendritic cells replaces pattern-recognition
　receptors in promoting CD8(+) T cell responses to influenza A virus.
　Nat Immunol. 2013 Jan 13;14(3):246-53.

2012
・Ito M, Yanagi Y, Ichinohe T*. Encephalomyocarditis virus viroporin 2B activates NLRP3
　inflammasome. PLoS Pathog. 2012 Aug;8(8):e1002857.

2011
・Komune N, Ichinohe T*, Ito M, Yanagi Y. Measles virus V protein inhibits NLRP3
　inflammsome-mediated interleukin-1β secretion. J Virol. 2011 Dec;85(24):13019-26.

・Ichinohe T, Pang IK, Kumamoto Y, Peaper D, Ho JH, Murray TS, Iwasaki A. Microbiota 　
　regulates immune defense against respiratory tract influenza A virus infection.
　Proc Natl Acad Sci U S A. 2011 March 29;108(13):5354-9.

・Ichinohe T*, Yanagi Y. Recognition of viruses by inflammasomes. Fukuoka Igaku Zasshi.　
　2011 Feb;102(2):21-30. Review.

2010
・Ichinohe T*. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and
　immunity: impact on vaccine design. Expert Rev Vaccines. 2010 Nov;9(11):1315-24. Review.

・Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M,
　Takahashi H, Strayer DR, Carter WA, Chiba J, Tamura S, Sata T, Kurata T, Hasegawa H.
　Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with
　the highly pathogenic influenza A H5N1 virus. J Med Virol. 2010 Oct;82(10):1754-61.

・Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular
　 M2 ion channel. Nature Immunol. 2010 May;11(5):404-10.

・Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, Hasegawa H. Zymosan enhances
　the　mucosal adjuvant activity of poly(I :C) in a nasal influenza vaccine. J Med Virol. 2010
　Mar;82(3):476-84.

・Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H,
　Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H. Induction of cross-protective
　immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom
　mycelia. J Med Virol. 2010 Jan;82(1):128-37.

2009
・Ichinohe T*, Iwasaki A. Inflammasomes in viral infection. Uirusu. 2009 Jun;59(1):13-21.
　Review.

・Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. PolyI:polyC12U adjuvant-combined
　intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
　Vaccine. 2009 Oct 23;27(45):6276-9.

・Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T. Development of mucosal adjuvants for
　intranasalvaccine for H5N1 influenza viruses. Ther Clin Risk Manag. 2009 Feb;5(1):125-32.

・Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A.Inflammasome recognition of influenza virus
　is essential for adaptive immune responses. J Exp Med. 2009 Jan 16;206(1):79-87.

-2008
・Ichinohe T*, Iwasaki A, Hasegawa H. Innate sensors of influenza virus: clues to developing
　better intranasal vaccines. Expert Rev Vaccines. 2008 Nov;7(9):1435-45. Review.

・Kamijuku H*, Nagata Y*, Jiang X*, Ichinohe T*, Tashiro T, Mori K, Taniguchi M, Hase K,
　Ohno H,Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI.
　Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide,
　which can induce cross-protection against influenza viruses. Mucosal Immunol. 2008 　　
　May;1(3):208-18.

・Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M,
　Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T,
　Hasegawa H. Cross-protection against H5N1 influenza virus infection is afforded by intranasal
　inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007 Nov
　1;196(9):1313-20.

・Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Ninomiya A, Imai M, Itamura S,
　Odagiri T, Tashiro M, Chiba J, Sata T, Kurata T, Hasegawa H. Intranasal immunization
　with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against
　homologous and heterologous virus challenge. Microbes Infect. 2007 Sep;9(11):1333-40.

・Ichinohe T, Nagata N, Strong P, Tamura S, Takahashi H, Ninomiya A, Imai M, Odagiri T, Tashiro
　M, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. Prophylactic effects of chitin microparticles
　on highly pathogenic H5N1 influenza virus. J Med Virol. 2007 Jun;79(6):811-9.

・Hasegawa H, Ichinohe T, Tamura S, Kurata T. Development of a mucosal vaccine for influenza
　viruses: preparation for a potential influenza pandemic. Expert Rev Vaccines. 2007
　Apr;6(2):193-201. Review.

・Asahi-Ozaki Y, Itamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M,
　Tashiro M, Sata T, Kurata T, Hasegawa H. Intranasal administration of adjuvant-combined
　recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
　Microbes Infect. 2006 Oct;8(12-13):2706-14.

・Maeda M, Sawa H, Tobiume M, Tokunaga K, Hasegawa H, Ichinohe T, Sata T, Moriyama M,
　Hall WW, Kurata T, Takahashi H. Tristetraprolin inhibits HIV-1 production by binding to genomic
　RNA. Microbes Infect. 2006 Sep;8(11):2647-56.

・Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H,
　Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H. Protection against
　influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an
　adjuvant. J Med Virol. 2006 Jul;78(7):954-63.

・Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T,
　Tsunetsugu-Yokota Y, Katano H, takahashi H, Matsuda J, Sata T, Kurata T, Nagashima K, hall
　WW. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human
　T-lymphotropic virus type I. Nat Med. 2006 Apr;12(4):466-72.

・Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J,
　Kurata T, Sata T, Hasegawa H. Synthetic double-stranded RNA poly(I:C) combined
　with mucosal vaccine protects against influenza virus infection. J Virol. 2005 Mar;79(5):2910-9.

・Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H,
　Chiba J, Kurata T, Sata T. Protection against influenza virus infection by intranasal
　administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol.
　2005 Jan;75(1):130-6.

・Watanabe I, Ross TM, Tamura S, Ichinohe T, Ito S, Takahashi H, Sawa H, Chiba J, Kurata T,
　Sata T, Hasegawa H. Protection against influenza virus infection by intranasal administration of
　C3d-fused hemagglutinin. Vaccine. 2003 Nov 7;21(31):4532-8.